MedTrace Logo

ArTificial inTelligence-based RAdiogenomics in Colon Tumors

NCT06108310 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-10-31

No results posted yet for this study

Summary

The goal of this clinical trial is to develop an artificial intelligence-based model to assess radiogenomics signature of colon tumor in patients with stage II-III colon cancer. The main question it aims to answer is:

• Can artificial intelligence-based algorithm of radiomics features combined with clinical factors, biochemical biomarkers, and genomic data recognise tumor behaviour, aggressiveness, and prognosis, identifying a radiogenomics signature of the tumor?

Participants will

* undergo a preoperative contrast-enhanced CT examination;
* undergo surgical excision of colon cancer
* undergo adjuvant therapy if deemed necessary based on current guidelines

Conditions

  • Colon Cancer Stage II
  • Colon Cancer Stage III

Sponsors & Collaborators

  • Associazione Italiana per la Ricerca sul Cancro

    collaborator OTHER

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Andrea Laghi, MD · University of Roma La Sapienza

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-02
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06108310 on ClinicalTrials.gov